Peptide receptor radionuclide therapy effective and safe as salvage therapy for gastro-entero-pancreatic and bronchial neuro-endocrine tumours

Tumour response rates after initial treatment with peptide receptor radionuclide therapy (PRRT) have proven clinical benefit; however, complete response is uncommon. It is more likely than not that residual tumours will develop and progress again, and re-treatment with extra cycles of PRRT as salvage therapy can be considered when safer and more efficient alternatives are not available.
Targeted Oncology